Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY, from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence issues positive guidance recommending CASGEVY’s use in the NHS. The United Kingdom Medicines and Healthcare products Regulatory Agency granted CASGEVY the first authorization in the world for a CRISPR-based gene-editing therapy on November 15, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Buffett trims Apple stake, delay worries dent Nvidia: Monday Buzz
- Buffett cuts Apple, Tyson reports Q3 beat: Morning Buzz
- PayPal, Kellanova upgraded: Wall Street’s top analyst calls
- Vertex Pharmaceuticals price target raised to $550 from $508 at Truist
- Vertex Pharmaceuticals price target raised to $550 from $500 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com